Get the Stockscreener App
32.85
1.20%
0.39
Pre-market:
32.99
0.14
+0.43%
Royalty Pharma Plc stock is traded at $32.85, with a volume of 3.25M.
It is up +1.20% in the last 24 hours and up +1.58% over the past month.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
See More
Previous Close:
$32.46
Open:
$32.31
24h Volume:
3.25M
Relative Volume:
0.82
Market Cap:
$14.23B
Revenue:
$2.27B
Net Income/Loss:
$1.15B
P/E Ratio:
12.88
EPS:
2.55
Net Cash Flow:
$2.80B
1W Performance:
-2.72%
1M Performance:
+1.58%
6M Performance:
+19.24%
1Y Performance:
+8.24%
1-Day Range:
$32.00
$32.91
1-Week Range:
$32.00
$33.79
52-Week Range:
$24.05
$34.20
Royalty Pharma Plc Stock (RPRX) Company Profile
Name
Royalty Pharma Plc
Sector
Industry
Phone
(212) 883-0200
Address
110 EAST 59TH STREET, NEW YORK, NY
Compare RPRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
32.85 | 14.23B | 2.27B | 1.15B | 2.80B | 2.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
495.42 | 127.22B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
689.50 | 75.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.45 | 35.94B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.43 | 31.38B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.84 | 26.84B | 3.32B | -860.46M | -1.04B | -8.32 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-03-24 | Downgrade | UBS | Buy → Neutral |
| Jun-14-22 | Resumed | UBS | Buy |
| May-13-22 | Initiated | Scotiabank | Sector Outperform |
| Apr-27-22 | Initiated | Goldman | Buy |
| Apr-14-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Oct-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Jul-30-21 | Initiated | Tigress Financial | Buy |
| Nov-09-20 | Upgrade | UBS | Neutral → Buy |
| Jul-14-20 | Initiated | Evercore ISI | In-line |
| Jul-13-20 | Initiated | BofA Securities | Buy |
| Jul-13-20 | Initiated | Citigroup | Neutral |
| Jul-13-20 | Initiated | Cowen | Outperform |
| Jul-13-20 | Initiated | Goldman | Neutral |
| Jul-13-20 | Initiated | JP Morgan | Neutral |
| Jul-13-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-13-20 | Initiated | SunTrust | Buy |
| Jul-13-20 | Initiated | UBS | Neutral |
View All
Royalty Pharma Plc Stock (RPRX) Latest News
Machina Capital S.A.S. Sells 12,740 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) Shares Purchased by Charles Schwab Investment Management Inc. - MarketBeat
River Road Asset Management LLC Sells 70,657 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Amundi Sells 1,137,257 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Bank of New York Mellon Corp Trims Stake in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) Shares Sold by Menlo Advisors LLC - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) Stock Holdings Lifted by New South Capital Management Inc. - MarketBeat
Proficio Capital Partners LLC Invests $786,000 in Royalty Pharma plc (NASDAQ:RPRX) - Defense World
Metis Global Partners LLC Raises Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) Shares Sold by Plato Investment Management Ltd - MarketBeat
Truist Financial Corp Acquires New Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Bank of New York Mellon Corp Cuts Stock Position in Royalty Pharma plc (NASDAQ:RPRX) - Defense World
Principal Financial Group Inc. Has $513,000 Holdings in Royalty Pharma plc (NASDAQ:RPRX) - Defense World
Torray Investment Partners LLC Has $17.45 Million Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
SBI Securities Co. Ltd. Purchases New Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Brokerages Set Royalty Pharma plc (NASDAQ:RPRX) PT at $41.60 - MarketBeat
Analysts Set Royalty Pharma plc (NASDAQ:RPRX) PT at $41.60 - Defense World
Royalty Pharma plc (NASDAQ:RPRX) Shares Sold by Amalgamated Bank - Defense World
Los Angeles Capital Management LLC Sells 346,803 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Marathon Asset Management Ltd Sells 46,981 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Illinois Municipal Retirement Fund Acquires 37,136 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Fjarde AP Fonden Fourth Swedish National Pension Fund Has $3.23 Million Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
New York State Common Retirement Fund Has $6.81 Million Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma (NASDAQ:RPRX) Reaches New 12-Month HighHere's What Happened - MarketBeat
Royalty Pharma to Present at TD Cowen's 45th Annual Health Care Conference - The Manila Times
What Will Royalty Pharma Reveal at TD Cowen's Healthcare Conference Next Week? - StockTitan
Royalty Pharma plcOrdinary SharesClass A to Host Earnings Call - ACCESS Newswire
Royalty Pharma plc (NASDAQ:RPRX) Shares Acquired by Allworth Financial LP - Defense World
New York State Common Retirement Fund Lowers Holdings in Royalty Pharma plc (NASDAQ:RPRX) - Defense World
Sanctuary Advisors LLC Grows Position in Royalty Pharma plc (NASDAQ:RPRX) - Defense World
8,998 Shares in Royalty Pharma plc (NASDAQ:RPRX) Purchased by Vontobel Holding Ltd. - MarketBeat
ING Groep NV Invests $2.92 Million in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Handelsbanken Fonder AB Has $11.74 Million Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma stock hits 52-week high at $33.71 amid growth - Investing.com Australia
Royalty Pharma Plc Stock (RPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):